Inappropriate use of progression-free survival in cancer drug approvals
The aim of cancer drugs is to prolong life or improve its quality. Yet only a third of cancer drugs entering the market in Europe and the US have evidence of overall benefits in survival or quality…
Read Original Article: Inappropriate use of progression-free survival in cancer drug approvals »
